Asp Isotopes Inc. · NASDAQ:ASPI
Asp Isotopes — Investor Presentation (January 2025)
43 slides from Asp Isotopes's investor presentation, January 2025
Slide 1: Corporate Overview
Corporate Overview January 2025 © ASP Isotopes Inc. 1
Slide 2: Forward Looking Statements
Forward Looking Statements Forward Looking Statements This presentation contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looki
Slide 3: ASP Isotopes: At a Glance
ASP Isotopes: At a Glance ASPI's advanced technology leverages 20 years of R&D history to enrich isotopes in varying levels of atomic mass. Our goal is to use innovative technology to become an indispensable supplier of enriched isotopes to three multi-billion-dollar end markets. Medical Opportunity
Slide 4: Target Milestones – 2025
Target Milestones – 2025 Market Target Milestones Operational Target Milestones • Secure at least 3 additional supply agreements • Start commercial production of isotopes at our for isotopes critical for new technologies and enrichment facilities in South Africa. –1Q 2025 healthcare. • Start constru
Slide 5: What is an Isotope?
What is an Isotope? • Isotopes are variations of atoms, the smallest units of matter that retain all the chemical properties of an element. Isotopes are forms of a chemical element with specific properties. • Atoms with the same number of protons but different numbers of neutrons are known as isotop
Slide 6: Isotope Supply Chain
Isotope Supply Chain Isotopes have one of the most severely compromised supply chains of 15% any material in the world and are critical to many end markets including nuclear medicine, energy, food and water: • Global isotope production is dominated by Russia (85%) 85% with the remainder produced in
Slide 7: Our Technologies
Our Technologies Aerodynamic Separation Process (ASP) Quantum Enrichment (QE) The Aerodynamic Separation Process utilizes gaseous Quantum Enrichment technology employs precisely tuned diffusion via a stationary wall centrifuge paired with lasers and quantum mechanical principles to efficiently propr
Slide 8: ASP Technology: Illustrative Separation Segment and Element Recovery
ASP Technology: Illustrative Separation Segment and Element Recovery © ASP Isotopes Inc. 8
Slide 9: ASP Isotopes: Technology Highlights
ASP Isotopes: Technology Highlights Cost-Effective Isotope enrichment facilities using our technology can be constructed at a fraction of capital cost and time vs. traditional isotope separation facilities. Modular, Scalable Design The plants can be small in footprint and modular in design, allowing
Slide 10: The Opportunity in Nuclear Medicine
The Opportunity in Nuclear Medicine © ASP Isotopes Inc. 10
Slide 11: The Opportunity in Nuclear Medicine
The Opportunity in Nuclear Medicine • The global medical isotope market generated $5.1 billion in 2022 and is anticipated to generate $11.4 billion by 2032.2 • Benefitting from increased regulatory approvals and R&D spend in the radiopharmaceuticals sector. • Pipeline advancements have created multi
Slide 12: Nuclear Medicine: Isotopes of Interest
Nuclear Medicine: Isotopes of Interest End Market Carbon-Dating & Pharmacokinetic 14C Tracing 99Tc SPECT Scan Imaging 68Ga PET Scan Imaging 67Cu 64Cu Oncology Treatment Non-Hodgkin lymphoma, Prostate Cancer, NETs 177Lu Neuroendocrine Tumors NETs Short half-life Stable Isotopes Radioisotopes © ASP Is
Slide 13: Isotope End Markets: Ytterbium-176
Isotope End Markets: Ytterbium-176 (176Yb) Consensus Forecasts (US$) for Pluvicto Radiopharmaceutical Theranostics 176Yb Global Market Size Ytterbium-176 $1.8bn 176Yb Global Market Size The radiopharmaceutical theranostics market is expected to be worth $3.43bn by 2028, growing at a CAGR of 11.3%, w
Slide 14: Isotope End Markets: Zinc-68
Isotope End Markets: Zinc-68 (68Zn) ~75% of 68Ga market Positron emission tomography Structural demand not likely to be Supply Gap (PET) ~15x Increase in satisfied by Gallium-68 Market Demand generators Global Market Size4 68Ga Global Market Size5 $1.15B $127M 100% Supplied by Generators ~25% Suppli
Slide 15: Isotope End Markets: Molybdenum-100
Isotope End Markets: Molybdenum-100 (100Mo) Current Isotope Conversion Process 99Mo 99Tc Single-photon emission 99Tc Half-Life: 66 Hours Half-Life: 6 Hours computed tomography (SPECT) Technetium-99 Global Market Size3 99Tc Global Market Size3 ASP Isotope Conversion Process $4.61B $4.17B 100Mo 99Tc S
Slide 16: Isotope End Markets: Carbon-14
Isotope End Markets: Carbon-14 (14C) Historically, Russia has been the sole supplier of Carbon-14. Availability of the Medical tracing isotope since the start of 2022 has been intermittent and unreliable. Now customers Global Market Size $10m p/a are seeking alternative suppliers to meet their deman
Slide 17: Medical Isotopes – Timelines
Medical Isotopes – Timelines R&D Under Isotopes End-Market R&D Stage Anticipated Market Entry Technology Evaluation Construction Carbon-14 Pharma & Agrochem 1H 2025 ASP Molybdenum-100 2026 ASP Molybdenum-98 2026 ASP Ytterbium-176 2025 QE Zinc-67/68 Nuclear Medicine -- 202
Slide 18: The Opportunity in Semiconductors
The Opportunity in Semiconductors © ASP Isotopes Inc. 18
Slide 19: The Opportunity in Semiconductors: Materials
The Opportunity in Semiconductors: Materials ASPI can establish itself as an indispensable part of the semiconductor supply chain. Our Silicon-28 enrichment plant in South Africa • Using our proprietary technology and increasing capacity our goal is to become the world’s leading supplier of enriched
Slide 20: Silicon-28: Technological Breakthrough
Silicon-28: Technological Breakthrough • Electronics are relatively affordable because Silicon is cheap and abundant. But, although naturally occurring Silicon is a For many decades, researchers theorized that chips good conductor of electricity, it is not a good conductor of heat made of pure Silic
Slide 21: Plan for Growth: Scaling into New Isotopes
Plan for Growth: Scaling into New Isotopes Iceland is a desirable location for ASPI’s expansion for several reasons. Here we expect to produce multiple enriched Isotopes supported by long-term contracts with significant partners. Planned isotopes include Silicon-28, Germanium-72 & 74, Xenon-129, Deu
Slide 22: The Opportunity in Nuclear Energy
The Opportunity in Nuclear Energy © ASP Isotopes Inc. 22
Slide 23: The Problem is Well-Known...Solving it is not as Straightforward
The Problem is Well-Known...Solving it is not as Straightforward Global electricity production needs to double by 2050, and Net Zero targets have been set across the world. • During COP28, 24 countries backed a Ministerial Declaration calling for the tripling of global nuclear energy capacity by 205
Slide 24: SMR (Small Modular Reactors): Next Wave in Nuclear Energy
SMR (Small Modular Reactors): Next Wave in Nuclear Energy The world is moving to a new type of nuclear reactor: SMR TerraPower’s Natrium The US DOE has already committed billions of dollars to Advanced Reactor Design Program (ARDP) to facilitate and accelerate development of advanced reactors. • Mod
Slide 25: HALEU Supply: A Growing Concern for SMRs
HALEU Supply: A Growing Concern for SMRs • Current commercial light water reactors use low-enriched uranium Annual US Demand Growth for HALEU (LEU) fuel which has less than 5% 235U content. 700 • Many SMRs and advanced reactors will require High Assay Low 600 Enriched Uranium (HALEU) with 235U enric
Slide 26: Our Technology: What is Quantum Enrichment (QE)?
Our Technology: What is Quantum Enrichment (QE)? • Isotopes of every element have unique spectroscopic “signatures” defined by the electromagnetic radiation or “light” absorbed by their atoms from electron transitions. • QE separates two isotopes by taking advantage of the slight differences in the
Slide 27: Comparing and Contrasting Enrichment Methods
Comparing and Contrasting Enrichment Methods Atomic Vapor laser Isotope Separation of Isotopes by Laser Gaseous Diffusion Centrifugation Quantum Leap Energy Seperation (AVLIS) Excitation Cost High Capital Cost Capital 1/10 of Diffusion Low Capital, Small Size Low Capital, Small Size Low Capital, Sma
Slide 28: Why Quantum Enrichment?
Why Quantum Enrichment? • Atomic spectroscopy – multiple selective lasers increase photoionization yield well over 70%. • Address quantum-forbidden transitions. • High-power, high-spec, and high repetition rate pump lasers. • Superior laser beam profiling, shaping, and combination. • Atomic beam col
Slide 29: Quantum Enrichment: Real World Experience
Quantum Enrichment: Real World Experience Our team have used lasers to enrich many different metals Laser Enrichment of Lithium 6 Heavy isotope >90% • Uranium • Lithium (the only isotopes where results have been published) Light isotope <10% • Ytterbium • Zirconium • Zinc Light isotope >90% The sepa
Slide 30: Nuclear Fuel: Supply Chain and Prices
Nuclear Fuel: Supply Chain and Prices • Uranium supply has been in a state of sustained deficit since 2018, which is widening due to years of underinvestment in uranium assets, resulting in production issues from the world's largest suppliers. • Meanwhile, demand for front-end nuclear fuel (U3O8, UF
Slide 31: Implications for HALEU
Implications for HALEU • If available (currently there is no Western supplier of HALEU), HALEU would likely cost >$18,000 per Kg. • Many SMR companies based their business plans assuming HALEU <$10,000 per Kg. We believe Quantum Enrichment may allow for HALEU production at significantly lower prices
Slide 32: Potential to Close the Loop on Nuclear Waste
Potential to Close the Loop on Nuclear Waste Depleted tails from other uranium enrichers produce nuclear waste. The management of this waste is becoming a problem. We believe that our technology can process this waste into HALEU - Potentially providing a solution to this growing environmental proble
Slide 33: Investment Overview
Investment Overview Leverage the following… To capitalize on three multi-billion- dollar opportunities… Proven Proprietary Technology ASPI's advanced technologies leverage 20 years of R&D history to enrich isotopes in varying levels of atomic mass, allowing it to meet the growing demand in the Nucle
Slide 34: Appendix
Appendix © ASP Isotopes Inc. 34
Slide 35: Current Group Structure
Current Group Structure • Most customers contract through ASPI Guernsey • We plan to spin-out Quantum Leap Energy (QLE) as a separate • Intellectual property largely owned by ASPI (UK) public company and list the shares of QLE on a U.S. national ASP Isotopes Inc. Delaware (US) exchange and distribut
Slide 36: Company History
Company History February October 2024 4Q 2023 2024 • ASPI demonstrates enrichment of October 2021 • Formation of Quantum ASPI announces Ytterbium-176 during Leap Energy focused on planned spin-out of commissioning phase of the first • ASPI wins competitive auction for nuclear fuels QLE and raises Qu
Slide 37: One of the Most Experienced Laser Groups in the World
One of the Most Experienced Laser Groups in the World Our team has designed and constructed lasers for the following customers… © ASP Isotopes Inc. 37
Slide 38: ASPI: Employees Demographics
ASPI: Employees Demographics We now have over 130 employees... 19% of employees have PhDs 41% of employees have advanced degrees or higher Employees By Nationality Employees By Role Radioisotope Engineering, Non South African Production and 15% 3% distribution, 23% Adminstration Plant 12% constructi
Slide 39: ASP Isotopes: Leadership Team
ASP Isotopes: Leadership Team PAUL MANN HENDRIK STRYDOM, PhD GERDUS KEMP, MD, PhD Chairman, and CEO Director, Chief Technology Officer Medical Director, CEO PET Labs • Co-founded ASP Isotopes in • Co-developer of “Aerodynamic • CEO Pet-Labs, a South African September 2021 Separation Process” (ASP) a
Slide 40: ASP Isotopes: Senior Management
ASP Isotopes: Senior Management Xandra Van Heerden, PhD Heino Van Wyk Heather Kiessling Robert Ainscow Head of R&D Head of Engineering Chief Financial Officer Chief Operating Officer ▪ Head of Research & ▪ Process engineer with ▪ 30+ years experience with life ▪ Co-Founder, ASP Development at ASP. d
Slide 41: ASP Isotopes: Scientific Advisors
ASP Isotopes: Scientific Advisors SERGEY VASNETSOV Consultant and Chemical Engineer ▪ Founder and Managing Director of ChemBridges, strategy consulting firm, since 2016. ▪ SVP of Strategy and M&A at LyondellBasell (NYSE: LYB) (2010-2016). ▪ Managing Director, Equity Research at Barclays Capital and
Slide 42: ASP Isotopes: Non-Executive Directors
ASP Isotopes: Non-Executive Directors PROF MIKE GORLEY, PhD TODD WIDER, MD DUNCAN MOORE, PhD ROB RYAN Director Director Director Director ▪ Director of Fusion ▪ Executive Chairman and ▪ Partner at East West ▪ 30+ years private investor Technology at the U.K. Chief Medical Officer, Capital Partners,
Slide 43: Data Sources
Data Sources 1. Meeting Isotope Needs and Capturing Opportunities for the Future: the 2015 Long Range Plan for the DOE Isotope Program https://www.osti.gov/servlets/purl/1298983 2. Medical Isotope Market to Reach $11.4 Billion Globally By 2032 | CAGR:8.8% : Allied Market Research Medical Isotope Mar